

**BEST AVAILABLE COPY**

Sheet 1 of 1

Form PTO-1449 (Rev. 3-03)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number		Application Number	
				00509/2/US		10/414,852	
				First Named Inventor			
				Kevin E. Henegar			
				Filing Date		Group Art Unit	
				April 16, 2003		Unknown	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial*		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date If Appropriate
<i>H</i>		US 6,121,451	Sep 19, 2000	Henegar et al.	546	92	
Examiner <i>Raymond Corrado</i>		Date Considered <i>11/20/03</i>					
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

**BEST AVAILABLE COPY**

## BEST AVAILABLE COPY



Sheet 1 of 1

Form PTO-949 (Rev. 1-2000)	U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. <b>00509/2/US</b>	Serial No. <b>10/414,852</b>
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant <b>Henegar, K.E.</b>		
		Filing Date <b>April 16, 2003</b>	Group No. <b>1614</b>	
OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)				
X		Josien et al. (1998) A general synthetic approach to the (20S)-camptothecin family of antitumor agents by a regiocontrolled cascade radical cyclization of aryl isonitriles. Chemistry – A European Journal 4(1), 67–83.		
Examiner <i>Raymond Gaylor</i>	Date Considered <i>11/20/03</i>			
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				